Table 1.

Characteristics and Outcomes of Leukemia Patients with COVID-19

Nr	Age	Sex	Leukemia type	Disease risk score	Disease phase	Treatment protocol	Time to COVID-19 diagnosis (days)	Symp-toms	Time to respiratory failure (days)	Treatment for respiratory failure	Anti-viral treatment	Anti-inflammatory treatment	COVID due treatment changes	Out-come of infection	Out-come	Sur-vival (days)
1	29	M	ALL	High	CR	GMALL Consolidation V	22	no	12	Oxygen	Favipiravir	Corticosteroid Tocilizumab	Discontinuation	R	A	24
2	40	F	ALL	High	Onset	GMALL Induction I	19	yes	0	Oxygen	Favipiravir	Corticosteroid Anakinra	Delay	R	A	18
3	30	M	ALL	High	CR	GMALL Consolidation	19	yes	-	-	Favipiravir	Corticosteroid	Delay	R	A	63
4	32	M	ALL	High	CR	BFMA 1A	3	yes	-	-	Favipiravir	Corticosteroid	Delay	R	A	61
5	30	M	ALL	Standard	Onset	GMALL Induction I	6	yes	-	-	Favipiravir	-	Delay	R	A	27
6	34	F	ALL	Standard	CR2	FLAG-IDA	56	no	-	-	Favipiravir	-	No change	R	A	82
7	34	M	ALL	Standard	Relapse	No treatment	-	no	-	-	Favipiravir	-	No change	R	A	80
8	57	M	AML	Favorable	Relapse	FLAG-IDA	12	yes	5	Oxygen, NIV, intubation	Favipiravir	Corticosteroid	No change	P	D	-
9	38	M	AML	Adverse	Onset	3+7 Induction	14	yes	5	Oxygen, NIV, intubation	Favipiravir	Corticosteroid	No change	P	D	-
10	49	M	AML	Intermediate	Onset	3+7 Induction	19	yes	4	Oxygen	Favipiravir	Corticosteroid	Delay	R	A	36
11	51	F	AML	Adverse	Onset	2+5 Induction	13	yes	0	Oxygen	Favipiravir	Corticosteroid Anakinra	Delay	R	A	18
12	33	M	AML M3	High	Onset	Not started yet	-	yes	7	NIV	Favipiravir	Corticosteroid	Delay	R	A	30
13	48	M	AML	Intermediate	CR	3+7 Induction	13	yes	2	Oxygen	Favipiravir	Hyperimmune plasma, Corticosteroid	Delay	R	A	85
14	46	M	AML M3	high	Onset	Not started yet	-	yes	-	-	Favipiravir	Corticosteroid	Dose reduction	R	A	59
15	48	M	AML M3	Intermediate	Refractory	ATRA	6	yes	6	Oxygen, intubation	Favipiravir	Corticosteroid Tocilizumab	Discontinuation	P	D	-
16	63	F	AML	Intermediate	Onset	3+7 Induction	7	yes	20	Oxygen, intubation	Favipiravir	Corticosteroid	No change	P	D	-
17	32	M	AML	Intermediate	Relapse	FLAG-IDA	17	yes	-	-	Favipiravir	-	-	R	A	180
18	71	F	AML	Adverse	Refractory	Azacytidine, Venetoclax	54	yes	?	Oxygen	Favipiravir	-	Delay	R	A	75
19	18	F	AML	Adverse	CR	HD Cytarabine	24	no	-	-	Favipiravir	-	Delay	R	A	131
20	63	F	AML	?	?	No treatment	-	yes	-	Intubation	Favipiravir	Corticosteroid	-	P	D	-
21	51	F	AML	Adverse	Onset	3+7 Induction	25	yes	1	Oxygen, NIV	Favipiravir	-	No change	R	A	266
22	65	F	AML	Adverse	Onset	3+7 Induction	5	yes	1	Oxygen	Favipiravir	-	Dose reduction	R	A	37
23	49	F	AML	Adverse	Relapse	FLAG-IDA	17	yes	0	Oxygen, NIV, Intubation	Favipiravir	Corticosteroid	No change	P	D	-
24	62	F	AML	Adverse	Relapse	Best supportive care	-	?	?	?	?	?	?	P	D	-
25	49	F	AML	Intermediate	Onset	3+7 Induction	35	no	-	-	Favipiravir	-	No change	R	A	14
26	25	M	AML	Adverse	Onset	Not started yet	-	no	-	-	Favipiravir	-	No change	R	A	81
27	53	M	MPAL		Onset	FLAG-IDA	9	yes	5	Oxygen	Favipiravir	-	No change	R	A	19

MPAL: mixed-phenotype acute leukemia; Time to COVID-19 diagnosis: from the first day of the last chemotherapy (days); CR: complete remission; Symptoms at the time of the diagnosis of COVID-19: Yes/No; NIV: non-invasive ventilation; Time to respiratory failure: calculated from COVID-19 diagnosis to respiratory failure (days); Outcome of infection: Progressed (P), Resolved (R); Outcome: Dead (D), or Alive (A); Survival: calculated from the time of recovery to the end of study (days).